Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $0.43.

  • Iradimed's EPS (Weighted Average and Diluted) rose 750.0% to $0.43 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.65, marking a year-over-year increase of 1301.37%. This contributed to the annual value of $1.45 for FY2024, which is 740.87% up from last year.
  • According to the latest figures from Q3 2025, Iradimed's EPS (Weighted Average and Diluted) is $0.43, which was up 750.0% from $0.45 recorded in Q2 2025.
  • Iradimed's 5-year EPS (Weighted Average and Diluted) high stood at $0.45 for Q2 2025, and its period low was $0.11 during Q1 2021.
  • In the last 5 years, Iradimed's EPS (Weighted Average and Diluted) had a median value of $0.32 in 2024 and averaged $0.31.
  • The largest annual percentage gain for Iradimed's EPS (Weighted Average and Diluted) in the last 5 years was 52000.0% (2021), contrasted with its biggest fall of 2142.86% (2021).
  • Iradimed's EPS (Weighted Average and Diluted) (Quarter) stood at $0.31 in 2021, then decreased by 3.23% to $0.3 in 2022, then grew by 20.0% to $0.36 in 2023, then dropped by 3.32% to $0.35 in 2024, then increased by 23.55% to $0.43 in 2025.
  • Its last three reported values are $0.43 in Q3 2025, $0.45 for Q2 2025, and $0.37 during Q1 2025.